- PR Newswire•4 hours agoAmpio Receives Guidance from the FDA and Proposes a Path for Approval for Single-Injection Ampion™ for the Treatment of Pain Due to Severe Osteoarthritis of the Knee
ENGLEWOOD, Colo., Feb. 27, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced that the Office of Tissue and Advanced Therapies (OTAT), a branch of the Center for Biologics Evaluation and Research (CBER) of the FDA, has recently provided additional guidance for the path to approval of Ampion™ as a treatment for pain due to severe Osteoarthritis of the knee (OAK). The FDA acknowledged an unmet medical need in patients with pain due to severe OAK, graded as Kellgren-Lawrence Grade 4 (KL 4), where there are currently no FDA approved treatments for this population.
- PR Newswire•7 months ago
ENGLEWOOD, Colo., Aug. 3, 2016 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today that it has filed a meeting request and Briefing Document with the FDA to seek guidance on the filing of the company's Biological License Application (BLA) for Ampion™ to treat patients suffering from pain caused by severe Osteoarthritis (OA) of the knee. In the second quarter of this year, Ampio submitted their Chemistry Manufacturing and Controls (CMC) documents for Ampion™ with the FDA, and requested the Agency provide any related guidance. Ampio also announced that the STRUT Study that treated pain due to OA of the knee with multiple injections of Ampion™, authored by Dr. John Schwappach, the trials Principal Investigator, was accepted for publication in the peer-reviewed journal "Orthopedics." As soon as the journal is in print, we will post the article on Ampio's website.
- TheStreet.com•8 months ago
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
AMPE : Summary for Ampio Pharmaceuticals, Inc. - Yahoo Finance
Ampio Pharmaceuticals, Inc. (AMPE)
NYSE MKT - NYSE MKT Real Time Price. Currency in USD
Add to watchlist
|Day's Range||0.83 - 0.95|
|52 Week Range||0.59 - 4.32|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.82|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|